Acting together, they change the transcriptional output of prostate cancer cells and lead to the loss of luminal and epithelial markers, such as AR, and the increase in the expression of basal and neuroendocrine-related genes [44, 45, 49–51] (Fig. 1b, c). The gene discussed is AR; the disease is prostate carcinoma.